Lyell Immunopharma, Inc. (LYEL): R&D Expense
$158.68M
Year ended 2025-12-31
-0.1%
3-year compound annual growth
-2.7%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $158.68M | -7.5% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $171.60M | -6.2% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $182.94M | +14.9% | 2026-03-12, From 2023-01-01 |
| 2022-12-31 | $159.19M | +14.8% | 2025-03-11, From 2022-01-01 |
| 2021-12-31 | $138.69M | -23.9% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $182.24M | +186.6% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $63.59M | n/a | 2022-03-29, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | $158.68M | -7.5% |
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | $3.64M | +19.5% |
| Impact Biomedical Inc. (IBO) | 2025-12-31 | $340.0K | +22.3% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $66.43M | -19.2% |
| Talphera, Inc. (TLPH) | 2025-12-31 | $6.03M | -10.2% |
| HCW Biologics Inc. (HCWB) | 2025-12-31 | $5.44M | -14.8% |
| Avalo Therapeutics, Inc. (AVTX) | 2025-12-31 | $50.08M | +105.0% |
| Jupiter Neurosciences, Inc. (JUNS) | 2025-12-31 | $2.09M | +323.5% |
| Connect Biopharma Holdings Ltd (CNTB) | 2025-12-31 | $37.80M | +29.2% |
Compare LYEL, NTHI, IBO, ALT side by side · Screen every company in Pharmaceutical Preparations ↗